Warfarin (Coumadin) — Competitive Intelligence Brief

Warfarin (Coumadin) (Warfarin (Coumadin)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin K antagonist (oral anticoagulant). Area: Cardiovascular.

marketed Vitamin K antagonist (oral anticoagulant) Vitamin K epoxide reductase (VKORC1) Cardiovascular Small molecule

Target snapshot

Warfarin (Coumadin) (Warfarin (Coumadin)) — University of Michigan. Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by blocking the enzyme vitamin K epoxide reductase, thereby reducing the formation of blood clots.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Warfarin (Coumadin) TARGET	Warfarin (Coumadin)	University of Michigan	marketed	Vitamin K antagonist (oral anticoagulant)	Vitamin K epoxide reductase (VKORC1)
warfarin accordingly INR value	warfarin accordingly INR value	Azienda Ospedaliera Universitaria Policlinico	marketed	Vitamin K antagonist (oral anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)
Warfarin or coumadin	Warfarin or coumadin	Ottawa Heart Institute Research Corporation	marketed	Vitamin K antagonist (oral anticoagulant)	Vitamin K epoxide reductase complex 1 (VKORC1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin K antagonist (oral anticoagulant) class)

1. Azienda Ospedaliera Universitaria Policlinico · 1 drug in this class
2. Ottawa Heart Institute Research Corporation · 1 drug in this class
3. University of Michigan · 1 drug in this class